Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

Pile of papers on a desk

Launching in the February issue of Nature Reviews Immunology, the Preprint Watch column is designed to provide rapid and open access to early data on both COVID-19 and non-COVID-19 immunology preprints. The first two reviews are: Super(antigen) target for SARS-CoV-2 and Sensing our Z-RNA.

During the COVID-19 pandemic the pace of scientific discovery and the race to find solutions required swift communication of results and fuelled an increase in immunology preprints. Journal club communities around the world seized the opportunity to evaluate and critically analyse a large number of SARS-CoV-2 preprints to provide independent insights to frontline researchers, to the general public, and to help prevent misinformation.

The journal group at Precision Immunology Institute at the Icahn School of Medicine, New York, and the OxImmuno Literature Initiative at the University of Oxford were both producing regular preprint summaries related to the COVID-19 emergency. Towards the end of 2020, the journal club teams from both institutes joined forces to launch the Oxford-Mount Sinai (OxMS) preprint journal club. During a weekly virtual joint ‘journal club’ they discuss selected preprints using their cross-institutional expertise and find the latest advancement in immunology. This new way of assessing and reviewing preprint literature may become a new approach to academic peer reviewing.

The full story is available on the Nuffied Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences (NDORMS) website

 

 

 

Similar stories

Oxford joins forces with 11 universities to launch social impact investment fund

The University of Oxford has joined forces with 11 leading universities to create Impact 12, an impact investment fund to support mission-led university ventures.

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Oxford University and partners win government funding to evaluate Paige Prostate Cancer Detection System

A prostate cancer detection software system to help pathologists quickly identify suspicious areas of tissue, developed by Paige, will be investigated in a multicentre clinical study led by Oxford University as part of a successful NHSx Artificial Intelligence Health and Care Award application.